Peter MacCallum Cancer Center,

Melbourne 3050

3 studies enrolling now · 8 studies all time

What they study most

Acute Myeloid Leukemia, Disease, Hodgkin, Endometrial Cancer, Invasive Mold Infections, Low-grade Serous Ovarian Cancer, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Malignant Melanoma Stage III, Mycosis Fungoides, Non-Hodgkin's Lymphoma, Recurrent Endometrial Cancer

Studies at this site

• A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — Recruiting now
• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers — Recruiting now
• A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections. — Recruiting now
• ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome — Recruiting now
• REtroperitoneal SArcoma Registry: an International Prospective Initiative — Recruiting now
• A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) — Completed
• Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma — Running, not enrolling
• A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 — NO_LONGER_AVAILABLE